medigraphic.com
ISSN 0016-3813 (Print)

2003, Number 5

<< Back Next >>

Gac Med Mex 2003; 139 (5)

Sentinel Node Biopsy in Melanoma Is Not Yet the Standard Treatment

Gallegos-Hernández JF, Nieweg OE, Tanis PJ, Valdés-Olmos RA, Kroon BBR

Language: Spanish
References: 27
Page: 449-452
PDF size: 62.07 Kb.


ABSTRACT

The trend to implement sentinel node biopsy as standard of care in patients with clinically localized melanoma is encouraged by the following three factors: the technique of lymphatic mapping has matured to the point that consensus was reached on how the procedure should be carried out, surgeons showed that they can find the node in nearly 100% of patients, and tumor-status was shown to be the most powerful prognostic factor.
However, recent studies revealed unfavorable new information that questions the wisdom of this trend.
Three studies published in 2001 with a combined total of 1,851 patients show false-negative rates of 16-25%. Another unnerving finding is the 13-19% incidence of in-transit metastases in patients with a tumor-positive sentinel node, reported by three groups. The ultimate purpose of lymphatic mapping is to provide sentinel node positive patients with early therapeutic measures, such as regional node dissection and adjuvant systemic treatment. However, there is currently no evidence that this approach results in improved regional control and survival.
Sentinel node biopsy can only become part of routine patient management if the tumor-status of the sentinel node carries clear implications of proven benefit for the manner in wich patients are managed and if regional control is not jeopardized.


REFERENCES

  1. Morton DL, Thompson JF, Essner R, Elashoff R, Stern SL, Nieweg OE, et al. Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Multicenter Selective Lymphadenectomy Trial Group. Ann Surg 1999;230:453-463.

  2. Gershenwald JE, Thompson W, Mansfield PF, Lee JE, Colome MI, Tseng CH, et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 1999;17:976-983.

  3. Jansen L, Nieweg OE, Peterse JL, Hoefnagel CA, Valdés Olmos RA, Kroon BBR. Reliability of sentinel lymph node biopsy for staging melanoma. Br J Surg 2000;87:484-489.

  4. Nieweg OE, Tanis PJ, Rutgers EJT. Summary of the second international sentinel node conference. Eur J Nucl Med 2001;28:646-649.

  5. Krag DN, Meijer SJ, Weaver DL, Loggie BW, Harlow SP, Tanabe KK, et al. Minimal-access surgery for staging of malignant melanoma. Arch Surg 1995;130:654-658.

  6. Albertini JJ, Cruse CW, Rapaport D, Wells K, Ross M, DeConti R, et al. Intraoperative radiolymphoscintigraphy improves sentinel node identification for patients with melanoma. Ann Surg 1996;223:217-224.

  7. Loggie BW, Hosseinian AA, Watson NE. Prospective evaluation of selective lymph node biopsy for cutaneous malignant melanoma. Am Surg 1997;63:1051-1057;discussion 1057-1058.

  8. Pijpers R, Borgstein PJ, Meijer S, Hoekstra OS, Van Hattum LH, Teule GJ. Sentinel node biopsy in melanoma patients: dynamic lymphoscintigraphy followed by intraoperative gamma probe and vital dye guidance. World J Surg 1997;21:788-792.

  9. Nieweg OE, Kapteijn BAE, Thompson JF, Kroon BBR. Lymphatic mapping and selective lymphadenectomy for melanoma: not yet standard therapy. Eur J Surg Oncol 1997;23:397-398.

  10. Clary BM, Brady MS, Lewis JJ, Coit DG. Sentinel lymph node biopsy in the management of patients with primary cutaneous melanoma: review of a large single-institutional experience with an emphasis on recurrence. Ann Surg 2001;233:250-258.

  11. Cascinelli N, Belli F, Santinami M, Fait V, Testori A, Ruka W, et al. Sentinel lymph node biopsy in cutaneous melanoma: the WHO melanoma program experience. Ann Surg Oncol 2000;7:469-474.

  12. Cascinelli N, Belli F, Santinami M, Patuzzo R. WHO Melanoma Programme: Results of sentinel node study Abstract. Melanoma Res 2001;11:221.

  13. Harlow SP, Krag DN, Ashikaga T, Weaver DL, Meijer SJ, Loggie BW, et al. Gamma probe guided biopsy of the sentinel node in malignant melanoma: a multicentre study. Melanoma Res 2001;11:45-55.

  14. Nieweg OE, Jansen L, Kroon BBR. Technique of lymphatic mapping and sentinel node biopsy for melanoma. Eur J Surg Oncol 1998;24:520-524.

  15. Cochran AJ, Balda BR, Starz H, Bachter D, Krag DN, Cruse CW, et al. The Augsburg Consensus. Techniques of lymphatic mapping, sentinel lymphadenectomy, and completion lymphadenectomy in cutaneous malignancies. Cancer 2000;89:236-241.

  16. Starz H. The Augsburg experience: histological aspects and patient outcomes. Sentinel Node 2000, Santa Monica December 1-4, 2000 (abstract) 2000; 20-21..

  17. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alpha-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996;14:7-17.

  18. Kirkwood JM, Ibrahim JG, Sosman JA, Sondak VK, Agarwala SS, Ernstoff MS, et al. High-dose interferon alpha-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 2001;19:2370-2380.

  19. Roses DF, Harris MN, Rigel D, Carrey Z, Friedman R, Kopf AW. Local and in-transit metastases following definitive excision for primary cutaneous malignant melanoma. Ann Surg 1983;198:65-69.

  20. Gershenwald JE, Schacherer C, Emerson M, Prieto VG, Berman R, Lee J, et al. Patterns of failure and survival in sentinel lymph node positive melanoma patients Abstract. Proceedings of ASCO 2001; 20:350a.

  21. Calabro A, Singletary SE, Balch CM. Patterns of relapse in 1001 consecutive patients with melanoma nodal metastases. Arch Surg 1989;124:1051-1055.

  22. McKay AJ. Surgical management of malignant melanoma. Br J Surg 1997;84:5-7.

  23. Anonymous. WHO declares lymphatic mapping to be the standaed of care for melanoma Abstract. Oncology 1999; 13:288.

  24. Reintgen DS, Cruse CW, Glass F, Fenske N. In support of sentinel node biopsy as a standard of care for patients with malignant melanoma. Dermatol Surg 2001;26:1070-1072.

  25. McMasters KM, Reintgen DS, Ross MI, Gershenwald JE, Edwards MJ, Sober A, et al. Sentinel lymph node biopsy for melanoma: controversy despite widespread agreement. J Clin Oncol 2001;19:2851-2855.

  26. Horton R. Surgical research or comic opera: questions, but few answers. Lancet 1996;347:984-985.

  27. Thomas JM. Melanoma: questions for the future. Eur J Surg Oncol 1996;22:130-133.




2020     |     www.medigraphic.com